Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 6,981 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma of the Breast Clear all
Completed Not applicable Interventional

MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors

NCT07782866
View directory record Official record
Conditions
Breast Cancer
Interventions
Transcutaneous vagus nerve and acupuncture point stimulation
Device
Lead sponsor
The Healing Consciousness Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Meadowbrook, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction

NCT04340180
View directory record Official record
Conditions
Breast Benign Tumor, Breast Malignant Tumor
Interventions
Standard of Care (SOC) gadolinium Breast MRI, reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Completed No phase listed Observational

Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity

NCT02274480
View directory record Official record
Conditions
Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients
Interventions
cardiac MRI with DWI
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 16, 2026, 6:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988
View directory record Official record
Conditions
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions
VLS-1488
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 16, 2026, 6:29 AM EDT
Recruiting Not applicable Interventional

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

NCT03941756
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Melanoma
Interventions
Indocyanine Green, Lymphangiography, Lymphovenous Bypass
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Completed No phase listed Observational

Body Composition and White Adipose Tissue Inflammation

NCT02713022
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Body Composition, White Adipose Tissue Inflammation
Interventions
DEXA Scan, Godin Leisure Time Exercise Questionnaire (GLTEQ)
Device · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
9
States / cities
Milford, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 16, 2026, 6:29 AM EDT
Terminated Phase 1 Interventional

Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

NCT01113970
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Indibulin
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Spokane, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 2 Interventional

Preoperative Cisplatin in Early Stage Breast Cancer

NCT00148694
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 16, 2026, 6:29 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

NCT05076266
View directory record Official record
Conditions
Breast Cancer, NOS
Interventions
Questionnaire
Other
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
45 Years to 75 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Withdrawn Not applicable Interventional

KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer

NCT02168179
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Skin Reactions Secondary to Radiation Therapy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
dermatologic complications management/prevention, questionnaire administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma

NCT00001270
View directory record Official record
Conditions
Breast Neoplasms, Lymphoma, Neoplasm Metastasis, Testicular Neoplasms
Interventions
interleukin-1
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17)

NCT01994369
View directory record Official record
Conditions
Resectable Breast Cancer
Interventions
EC17
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 16, 2026, 6:29 AM EDT
Terminated Phase 1 Interventional

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

NCT03294694
View directory record Official record
Conditions
Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer
Interventions
Ribociclib, PDR001, Fulvestrant
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 16, 2026, 6:29 AM EDT
Active, not recruiting Not applicable Interventional

Using Diagnostic Tools to Stage Breast Cancer

NCT00367666
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Completed No phase listed Observational

Role of Gene Variation in Effectiveness of Gleevec Treatment

NCT00342056
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 16, 2026, 6:29 AM EDT
Terminated Phase 2 Interventional Results available

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

NCT01919229
View directory record Official record
Conditions
Early Breast Cancer
Interventions
LEE011 (ribociclib), letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Fayetteville, Arkansas • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Not applicable Interventional Results available

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

NCT00428220
View directory record Official record
Conditions
Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exergaming Intervention and Breast Cancer Biomarkers in Black Women

NCT02152462
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
Exergaming
Other
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Results available

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

NCT00248170
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Anastrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
33 Years to 96 Years · Female only
Enrollment
4,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 16, 2026, 6:29 AM EDT
Active, not recruiting Not applicable Interventional

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

NCT01644669
View directory record Official record
Conditions
Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Interventions
Intra-operative Radiation Therapy - IORT
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
40 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 16, 2026, 6:29 AM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03972605
View directory record Official record
Conditions
Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

NCT00063570
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Pemetrexed, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Plantation, Florida • Morrisville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 3 Interventional

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 16, 2026, 6:29 AM EDT
Not listed Phase 2 Interventional

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

NCT00080756
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
therapeutic estradiol, deslorelin, therapeutic testosterone, therapeutic conventional surgery, active surveillance, quality-of-life assessment, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years to 48 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 16, 2026, 6:29 AM EDT